Tension-Free Vaginal Tape versus Polyacrylamide Hydrogel Bulking Agent for Stress Urinary Incontinence: Patient Choice and Outcomes in Finland.

IF 1.8 3区 医学 Q3 OBSTETRICS & GYNECOLOGY
Lotta Särkilahti, Camilla Isaksson, Tomi S Mikkola
{"title":"Tension-Free Vaginal Tape versus Polyacrylamide Hydrogel Bulking Agent for Stress Urinary Incontinence: Patient Choice and Outcomes in Finland.","authors":"Lotta Särkilahti, Camilla Isaksson, Tomi S Mikkola","doi":"10.1007/s00192-025-06119-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and hypothesis: </strong>Since 2018 we have offered polyacrylamide hydrogel (PAHG) injection as an alternative to tension-free vaginal tape (TVT) for primary stress urinary incontinence (SUI). Our study aim was to investigate patient choice, demographics, re-treatments, and complications for these procedures.</p><p><strong>Methods: </strong>Patient demographics were collected from the Hospital Registry for women with primary SUI treated with TVT or PAHG, including patient age, body mass index, smoking status, obstetric history, and prior pelvic surgeries. Re-treatments and complications were collected at 2-year follow-up after each primary procedure.</p><p><strong>Results: </strong>Among 391 primary procedures, 55% (n = 217) of women chose the TVT and 45% (n = 174) the PAHG treatment, with similar patient demographics. Within 2 years, the re-treatment rates were 0.9% (n = 2) for TVT and 27.0% (n = 47) for PAHG (p < 0.001). Among patients undergoing re-treatment after primary PAHG, 57.4% (n = 27) opted for re-injection and 42.6% (n = 20) chose a mid-urethral sling. Three patients received TVT after two PAHG injection treatments. Complications occurred in 14.3% and 9.2% after TVT and PAHG respectively (p = 0.124). Complications after TVT ranged from Clavien-Dindo grades I-IIIb, with 4.1% of patients requiring reoperations, whereas PAHG complications were grades I-II with no reoperations. Including re-treatments, complication rates were 14.3% (TVT) and 10.9% (PAHG; p = 0.322).</p><p><strong>Conclusions: </strong>Similar clinical profiles in both TVT and PAHG groups suggest no specific demographic factors predict decision making. After a 2-year follow-up, the overall complication rates were similar, with PAHG associated with a higher likelihood of requiring re-treatment, whereas TVT carried a greater risk of severe complications. The re-treatment rates were lower than previously reported, indicating that actual patients are fairly satisfied with their primary choice.</p>","PeriodicalId":14355,"journal":{"name":"International Urogynecology Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Urogynecology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00192-025-06119-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and hypothesis: Since 2018 we have offered polyacrylamide hydrogel (PAHG) injection as an alternative to tension-free vaginal tape (TVT) for primary stress urinary incontinence (SUI). Our study aim was to investigate patient choice, demographics, re-treatments, and complications for these procedures.

Methods: Patient demographics were collected from the Hospital Registry for women with primary SUI treated with TVT or PAHG, including patient age, body mass index, smoking status, obstetric history, and prior pelvic surgeries. Re-treatments and complications were collected at 2-year follow-up after each primary procedure.

Results: Among 391 primary procedures, 55% (n = 217) of women chose the TVT and 45% (n = 174) the PAHG treatment, with similar patient demographics. Within 2 years, the re-treatment rates were 0.9% (n = 2) for TVT and 27.0% (n = 47) for PAHG (p < 0.001). Among patients undergoing re-treatment after primary PAHG, 57.4% (n = 27) opted for re-injection and 42.6% (n = 20) chose a mid-urethral sling. Three patients received TVT after two PAHG injection treatments. Complications occurred in 14.3% and 9.2% after TVT and PAHG respectively (p = 0.124). Complications after TVT ranged from Clavien-Dindo grades I-IIIb, with 4.1% of patients requiring reoperations, whereas PAHG complications were grades I-II with no reoperations. Including re-treatments, complication rates were 14.3% (TVT) and 10.9% (PAHG; p = 0.322).

Conclusions: Similar clinical profiles in both TVT and PAHG groups suggest no specific demographic factors predict decision making. After a 2-year follow-up, the overall complication rates were similar, with PAHG associated with a higher likelihood of requiring re-treatment, whereas TVT carried a greater risk of severe complications. The re-treatment rates were lower than previously reported, indicating that actual patients are fairly satisfied with their primary choice.

无张力阴道带与聚丙烯酰胺水凝胶膨胀剂治疗压力性尿失禁:芬兰患者的选择和结果。
自2018年以来,我们提供聚丙烯酰胺水凝胶(PAHG)注射作为无张力阴道胶带(TVT)治疗原发性压力性尿失禁(SUI)的替代方案。我们的研究目的是调查这些手术的患者选择、人口统计学、再治疗和并发症。方法:从医院登记处收集接受TVT或PAHG治疗的原发性SUI妇女的患者人口统计资料,包括患者年龄、体重指数、吸烟状况、产科史和既往盆腔手术。在每次初次手术后的2年随访中收集再次治疗和并发症。结果:在391例初级手术中,55% (n = 217)的女性选择TVT, 45% (n = 174)的女性选择PAHG治疗,患者人口统计学相似。2年内,TVT的再治疗率为0.9% (n = 2), PAHG的再治疗率为27.0% (n = 47) (p < 0.001)。在原发性PAHG后再次治疗的患者中,57.4% (n = 27)的患者选择再注射,42.6% (n = 20)的患者选择尿道中吊带。3例患者经两次PAHG注射治疗后出现TVT。TVT和PAHG术后并发症发生率分别为14.3%和9.2% (p = 0.124)。TVT后并发症Clavien-Dindo分级为I-IIIb级,4.1%的患者需要再手术,而PAHG并发症为I-II级,无再手术。包括再治疗在内,并发症发生率分别为14.3% (TVT)和10.9% (PAHG);P = 0.322)。结论:TVT组和PAHG组相似的临床特征表明,没有特定的人口统计学因素可以预测决策。经过2年的随访,总体并发症发生率相似,PAHG需要再次治疗的可能性更高,而TVT则有更大的严重并发症风险。再治疗率低于先前报道,表明实际患者对他们的首选相当满意。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.80
自引率
22.20%
发文量
406
审稿时长
3-6 weeks
期刊介绍: The International Urogynecology Journal is the official journal of the International Urogynecological Association (IUGA).The International Urogynecology Journal has evolved in response to a perceived need amongst the clinicians, scientists, and researchers active in the field of urogynecology and pelvic floor disorders. Gynecologists, urologists, physiotherapists, nurses and basic scientists require regular means of communication within this field of pelvic floor dysfunction to express new ideas and research, and to review clinical practice in the diagnosis and treatment of women with disorders of the pelvic floor. This Journal has adopted the peer review process for all original contributions and will maintain high standards with regard to the research published therein. The clinical approach to urogynecology and pelvic floor disorders will be emphasized with each issue containing clinically relevant material that will be immediately applicable for clinical medicine. This publication covers all aspects of the field in an interdisciplinary fashion
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信